Akebia Therapeutics Inc.
AKBA | NASDAQ
$1
+$0.06 (+6.55%)
Sep 22, 2026, 2:09 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -77.40 | -5.76 | -4.43 | -0.99 | -1.53 | -1.11 |
PEG Ratio | 0.83 | -0.32 | 0.09 | 0.02 | 0.04 | -0.15 |
PS Ratio | 1.75 | 2.50 | 1.19 | 0.36 | 1.77 | 1.32 |
PB Ratio | 12.70 | -8.15 | -7.60 | 20.17 | 5.07 | 1.57 |
P/FCF Ratio | 6.09 | -9.85 | -9.94 | -1.44 | -1.48 | -3.50 |
P/OCF Ratio | 6.09 | -9.86 | -9.94 | -1.44 | -1.48 | -3.51 |
OCF/S Ratio | 28.79 | -25.38 | -12.02 | -25.01 | -119.52 | -37.46 |
Debt / Equity Ratio | 6.63 | -3.84 | -3.41 | 19.08 | 2.56 | 0.51 |
Quick Ratio | 1.04 | 1.21 | 1.03 | 1.26 | 0.90 | 1.66 |
Current Ratio | 1.13 | 1.41 | 1.18 | 1.43 | 1.04 | 1.98 |
Asset Turnover | 0.63 | 0.73 | 0.81 | 0.82 | 0.40 | 0.46 |
Interest Coverage | 0.97 | -2.78 | -7.67 | -5.15 | -13.27 | -42.59 |
Return on Equity | -16.39% | 141.12% | 169.78% | -1.8K% | -381.07% | -155.42% |
Return on Assets | -1.42% | -31.45% | -21.48% | -26.46% | -53.28% | -59.74% |
Return on Invested Capital | 9.26% | -33.77% | -27.89% | -30.68% | -71.36% | -81.73% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 83.29% | 60.56% | 61.90% | 92.31% | 61.50% | 78.29% |
Net Profit Margin | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% | -130.61% |
Pretax Profit Margin | -1.58% | -43.33% | -26.68% | -32.22% | -133.25% | -130.61% |
Operating Profit Margin | 9.95% | -31.51% | -23.77% | -27.62% | -124.97% | -128.23% |
FCF Margin | 28.79% | -25.40% | -12.02% | -25.05% | -119.55% | -37.57% |
EBITDA Margin | 9.20% | -8.57% | -4.25% | 1.04% | -89.73% | -47.46% |
Add to Watchlist
Select watchlists to add or remove AKBA